3 key reasons why AstraZeneca’s share price looks a steal to me right now

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be getting a huge bargain.

| More on:
Young Caucasian girl showing and pointing up with fingers number three against yellow background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Only around five months ago, AstraZeneca’s (LSE: AZN) share price hit a point that made the firm the UK’s first £200bn listing.

Now, it is down 20% from its 3 September 12-month traded high of £133.38.

I think three key reasons will propel it much higher again over time.

Enormous earnings growth potential

Ultimately, it is earnings growth that powers a firm’s share price (and dividend) higher. Analysts forecast that AstraZeneca’s earnings will grow by 16.9% each year to the end of 2027.

Its nine-month results saw its 2024 earnings per share (EPS) growth forecast increase to a high-teens percentage from the mid-teens. This came after an 11% jump in EPS over the period to $6.12 (£4.97).

And both followed a 19% increase in total revenue, to $39.182bn. Revenue is the total income a company generates, while earnings are what remains after expenses are subtracted. In the long term, AstraZeneca forecasts $80bn+ in revenues by 2030, against $45.8bn at the end of 2023.

Positioned for a major demographic shift

According to the World Health Organization, 1.4bn people will be aged 60+ by 2030 compared to 1bn now. By 2050, that number will be 2.1bn. At that point, the number of people aged 80+ will triple to 426m.

As older age brings declining health, the demand for medical assistance, including drugs, increases.

AstraZeneca currently has 189 new drugs at various stages of development in its pipeline. By comparison, its leading UK peer GSK has 71.

Moreover, the firm announced at its 15 November ‘Health Equity Event’ that it is working on multiple game-changing new medicines. These focus on cutting-edge areas such as smart chemotherapy, gene therapy and editing, and next-generation immunotherapy.

Extreme current undervaluation

On the key price-to-book ratio of stock valuation, AstraZeneca trades at only 5.1. This is bottom of its competitor group, which averages 32.9. So, it looks very undervalued on this basis.

The same is true on the price-to-sales and price-to-earnings ratios. On the former, it trades at just 4 compared to its competitors’ average of 11. And on the latter, it is at 31.7 against a 53.9 average for its peers.

A discounted cash flow analysis shows the shares are currently 60% undervalued. Therefore, technically a fair price is £266.18 rather than the present £106.47.

They may go lower or higher than that, given market vagaries. But it underlines to me that they look a steal at the current price.

Will I buy more?

Against all this are two main risks in my view. The first is the possibility of penalties being imposed when Chinese authorities conclude their investigations of its China operations.

The second is legal action for damages from AstraZeneca’s alleged failure to inform investors early enough of these investigations.

That said, AstraZeneca raised its key performance guidance after China launched its investigations. Additionally, I see legal action against pharmaceutical firms as already largely costed into that business and the share price.

Consequently, I will be buying more AstraZeneca shares very soon.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Simon Watkins has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

Time to buy Nvidia shares before fresh all-time highs?

Nvidia shares began 2025 at an all-time high before a big drop in the last week or two. Our writer…

Read more »

Investing Articles

A top FTSE 100 share to consider for a Stocks and Shares ISA starter portfolio!

While not without risk, a lump sum in this FTSE 100 trust could prove a great way for Stocks and…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

I asked ChatGPT to name the best 5 UK shares to build wealth over 50 – and here they are!

Harvey Jones is looking to build a balanced portfolio of UK shares to fund his final years, and asked ChatGPT…

Read more »

Investing Articles

£10k invested in Scottish Mortgage shares after the DeepSeek crash is now worth…

Harvey Jones thought his Scottish Mortgage shares were heading for a bumpy ride when DeepSeek emerged last month. Then he…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

1 ex-penny stock up nearly 400% in my Stocks and Shares ISA! 

This writer is starting to take notice of a small-cap stock that is 'up' significantly in his ISA portfolio over…

Read more »

Investing Articles

The FTSE 100 index hits new highs! But will Legal & General shares outperform it in 2025?

Legal & General's share price has rocketed almost 8% so far in 2025. Can it continue to outstrip the surging…

Read more »

Investing Articles

Up another 8% in a week! So what’s stopping me from buying IAG shares? 

Harvey Jones is desperate to add high-flying IAG shares to his portfolio before they climb even higher but there's a…

Read more »

Happy couple showing relief at news
Investing Articles

The Bank of England’s slashed its growth forecast but the FTSE 100 doesn’t seem to care!

On the day the UK’s central bank halved its forecast for growth in 2025, the FTSE 100 reached a record…

Read more »